NRN1 protein abundance is comparable among controls and primary tauopathy cases, as well as Tau P301S mice and non-transgenic littermates at 3 and 9 months.<h4>Discussion</h4>These findings advance the investigation of NRN1 as a therapeutic candidate for AD. Here, MAPT is linked to tauopathy.